Abstract
Introduction
This analysis examines the historical and forecast performance for Novo
Nordisk in the Rx pharmaceutical sector. The profile encompasses global
company strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Key reasons to purchase this research
- Benchmark Novo Nordisk' s performance against key rivals in the
prescription pharmaceutical sector
- Assess the company' s highly focused strategy, centred on the use of
therapeutic proteins and internally sourced R&D
- Analyze how Novo Nordisk' s dominance in the diabetes market will elevate
the company to the Big Pharma peer set by 2010
| 
View Cart
